In 2015, almost $500 billion changed hands in a record-breaking number of mergers and acquisitions (M&A), globally. Drug portfolios were shuffled around and FDA approvals also had a record-breaking year with the most new drugs in over 60 years.
A variety of acquisitions and partnerships occurred as emerging technologies such as CRISPR genomic editing, CART-cell therapies and liquid biopsies for the treatment and monitoring of cancer gained significant momentum.
Onyva The Agency covers these exciting developments, with a full illustrated guide to M&As for 2015 and the start of 2016, in its new report.
____________________________________